Conversion surgery for perihilar cholangiocarcinoma after immune checkpoint inhibitor–combined chemotherapy with the biliary stent–based strategy
- 14 May 2026
- journal article
- Published by Elsevier in Surgical Oncology
- Vol. 66, 102448
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Successful Conversion Surgery in Advanced Hilar Cholangiocarcinoma Treated With Durvalumab Plus Gemcitabine and CisplatinThe American Surgeon™, 2025
- Conversion Surgery Performed Following Durvalumab Combined With Gemcitabine and Cisplatin in Cholangiocarcinoma: A Case ReportIn Vivo, 2025
- Feasibility of major hepatectomy following preoperative chemotherapy for advanced perihilar cholangiocarcinomaEuropean Journal of Surgical Oncology, 2024
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyThe Lancet Gastroenterology & Hepatology, 2024
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Comparison of double-layer large-diameter and conventional small-diameter plastic stents for preoperative biliary drainage in resectable distal malignant biliary obstructionScientific Reports, 2020
- Guidelines for the diagnosis and treatment of cholangiocarcinoma: an updateGut, 2012
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- The Clavien-Dindo Classification of Surgical ComplicationsAnnals of Surgery, 2009
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992